Rapid Infectious Disease Testing Market is anticipated to surpass USD 60.8 billion in 2031 at a CAGR of 6.9%

According to a research study published by Knowledge Sourcing Intelligence (KSI), the rapid infectious disease testing market will expand from USD 43.6 billion in 2026 to USD 60.8 billion in 2031 at a CAGR of 6.9% during the forecast period.

The market is expected to show steady and consistent growth because consumers are demanding fast, accurate, and more accessible diagnostic solutions for infectious diseases all over the world.

Access sample report or view details: https://www.knowledge-sourcing.com/report/rapid-infectious-disease-testing-market

Key Market Insight & Emerging Trends:

The rapid infectious disease testing market is expanding steadily, as healthcare systems increasingly prioritize early disease detection and outbreak control. The overall prevalence of infectious diseases, along with the need for prompt diagnosis, is pushing demand for fast testing technologies through hospitals, clinics, laboratories, and even home care settings.

Meanwhile, advances in molecular diagnostics and lateral flow assays are improving test sensitivity, specificity, and turnaround time. Also, the rising use of point-of-care testing tools is shifting disease management, because clinicians can make faster decisions, and there’s less dependence on centralized labs.

In addition, the growing public awareness about preventive healthcare, easier access to diagnostic services in emerging economies, and more funding for public health is also supporting market growth. Apart from this, the long-term consequences of the COVID-19 pandemic have propelled innovation in rapid testing approaches and helped strengthen diagnostic infrastructure worldwide.

• North America had the largest market share in 2025 because of its robust healthcare system and high penetration of rapid diagnostic technologies.

• By product type, rapid test kits were the most dominant as a result of their ease of use, cost-effectiveness, and accessibility.

• By technology, lateral flow assays were prominent in the market because of their instant results and ease of use at the point of care.

• By application, respiratory infections had the highest market share due to rising incidences of respiratory diseases caused by bacteria and viruses.

The market for rapid infectious disease tests is extremely competitive, with existing diagnostic manufacturers and new entrants concentrating on innovations and expansion into other regions.

Product Type Insights: Rapid Test Kits Leading Market Revenue

The rapid test kits accounted for the largest share, mainly because the demand for decentralized testing solutions is increasing. Their portability, fast turnaround times, and versatility make them popular among both home and clinical users in infectious diseases.

Technology Insights: Lateral Flow Assays Maintaining Strong Demand

Lateral flow assays are a critical technology in the market of rapid infectious disease tests due to their simplicity, cost-effectiveness, and instant results. Their high usage in the testing for COVID-19, HIV, and malaria has further boosted their market penetration.

Application Insights: Respiratory Infections Driving Testing Volumes

Respiratory infections held the dominant market share. This is supported by more influenza, RSV, COVID-19, and rising incidence of respiratory pathogens. In addition to this, the growing demand for rapid detection and better infection control continues to drive growth in this segment.

Regional Highlights: North America Leads, Asia Pacific Shows Strong Potential

North America stayed in the lead during 2025, driven by solid healthcare infrastructure, strong diagnostic awareness, and reimbursement policies that are more favorable. On the other hand, the Asia Pacific market will increase considerably during the forecast period, fueled by rising healthcare investments, wider diagnostic reach, and broader public health programs.

Competitive Landscape

The report profiles major players operating in the market, such as Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Danaher Corporation, bioMérieux, BD, QuidelOrtho Corporation, Hologic, SD Biosensor, and Access Bio. These companies are expanding their rapid testing lineups, improving manufacturing capacity, and working on next-generation point-of-care diagnostic options, mainly to align with the rising global need for infectious disease testing.

Market Segmentation

The report segments the rapid infectious disease testing market as follows:

• By Product Type

  • Rapid Test Kits

  • Instruments

  • Software & Services

• By Technology

  • Lateral Flow Assays

  • Immunoassays

  • Molecular Diagnostics

  • Isothermal Nucleic Acid Amplification

• By Application

  • Respiratory Infections

  • HIV Testing

  • Hepatitis Testing

  • Malaria Testing

  • COVID-19 Testing

• By Geography

  • North America

    • USA

    • Canada

    • Mexico

  • South America

    • Brazil

    • Argentina

    • Others

  • Europe

    • United Kingdom

    • Germany

    • France

    • Spain

    • Others

  • Middle East and Africa

    • Saudi Arabia

    • UAE

    • Others

  • Asia Pacific

    • China

    • India

    • Japan

    • South Korea

    • Indonesia

    • Thailand

    • Others

Companies Profiled:

• Abbott Laboratories

• Roche Diagnostics

• Thermo Fisher Scientific

• Danaher Corporation

• bioMérieux

• BD (Becton, Dickinson and Company)

• QuidelOrtho Corporation

• Hologic

• SD Biosensor

• Access Bio

Explore More Reports:

• Minimal Residual Disease Testing Market

• Syndromic Infectious Disease Diagnostics Market

• RUO Immunoassay Market